Tandon, N
Muchtar, E
Sidana, S
Dispenzieri, A
Lacy, M Q
Dingli, D
Buadi, F K
Hayman, S R
Chakraborty, R
Hogan, W J
Gonsalves, W
Warsame, R
Kourelis, T V
Leung, N
Kapoor, P
Kumar, S K
Gertz, M A
Article History
Received: 3 January 2017
Revised: 17 February 2017
Accepted: 1 March 2017
First Online: 10 April 2017
Competing interests
: Angela Dispenzieri: Celgene Corp. (research funding), Millennium Pharmaceuticals Inc. (research funding), Pfizer Inc. (travel grant) and Janssen Pharmaceuticals Inc. (research funding), MQL: Celgene Corp. (research funding), DD: Karyopharm Therapeutics (research funding), Amgen Inc. (research funding), Millenium Pharmaceuticals (Research funding). PK: Millennium Pharmaceuticals Inc. (Takeda Pharmaceutical Co. Limited; research funding), Celgene Corp. (research funding) and Onyx Pharmaceuticals Inc. (Amgen Inc.; research funding). MAG: Celgene Corp. (Honoraria), Millennium Pharmaceuticals Inc. (Consultancy and Honoraria), Onyx Pharmaceuticals Inc. (Honoraria), Novartis (Honoraria), Smith Kline (Honoraria), Prothena (Honoraria), Ionis (Honoraria), Amgen Inc. (Honoraria). SKK: Celgene Corp. (consultancy and research funding), Millennium Pharmaceuticals Inc. (consultancy and research funding), Novartis (research funding), Onyx Pharmaceuticals Inc. (consultancy and research funding), AbbVie (research funding), Janssen (consultancy and research funding), BMS (consultancy and research funding). The remaining authors declare no conflict of interest.